NEUROTROPE, INC. (OTCMKTS:NTRP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective on November 21, 2016, Neurotrope, Inc. (the Company)
amended its 2013 Equity Incentive Plan, as amended (the Plan) to
an Amendment to the Neurotrope, Inc. 2013 Equity Incentive Plan
(the Equity Incentive Plan Amendment) to increase the number of
shares of Common Stock available for issuance under the Plan to
21,930,300 shares of Common Stock. The foregoing description of
the Equity Incentive Plan Amendment is qualified in its entirety
by reference to the full text of the Equity Incentive Plan
Amendment, a copy of which is being filed as Exhibit 10.1 to this
Current Report on Form 8-K and is incorporated herein by
reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description | |
| 10.1 |
Amendment to the Neurotrope, Inc. 2013 Equity Incentive Plan, dated November 21, 2016 |
About NEUROTROPE, INC. (OTCMKTS:NTRP)
Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer’s disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD. NEUROTROPE, INC. (OTCMKTS:NTRP) Recent Trading Information
NEUROTROPE, INC. (OTCMKTS:NTRP) closed its last trading session up +0.023 at 0.320 with 1,502,151 shares trading hands.
